Effects of Drug Dosage in Hodgkin's Disease Treatment
Author Information
Author(s): P. Lagarde, F. Bonichon, H. Eghbali, I. de Mascarel, J. Chauvergne, B. Hoernj
Primary Institution: Fondation Bergonie
Hypothesis
How do dose intensity and density affect therapeutic and toxic effects in Hodgkin's disease?
Conclusion
Higher dose density correlates with better tumor response and disease-free survival in Hodgkin's disease treatment.
Supporting Evidence
- Higher dose density significantly correlates with leukocyte count drop (P<0.001).
- Disease-free survival is significantly related to dose density (P=0.050).
- After excluding marginal recurrences, dose intensity correlates with disease-free survival (P=0.031).
Takeaway
Giving more medicine per body size helps patients with Hodgkin's disease get better, but it can also make them feel sick.
Methodology
Patients received a fixed chemotherapy regimen (CVPP) followed by radiotherapy, with outcomes assessed based on leukocyte counts and tumor response.
Potential Biases
Potential bias due to the retrospective nature of the study and the lack of randomization.
Limitations
The study is retrospective and had a small sample size, which limits the ability to perform multivariate analysis.
Participant Demographics
Patients were aged over 15 years, with some cases of older patients and children included.
Statistical Information
P-Value
P=0.031
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website